Your browser doesn't support javascript.
loading
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
van der Weele, Linda; Pollastro, Sabrina; van Schaik, Barbera D C; van Kampen, Antoine H C; Niewold, Ilse T G; Kuijpers, Taco W; Warnke, Clemens; Jensen, Poul Erik H; Kramer, Daniel; Ryner, Malin; Hermanrud, Christina; Dönnes, Pierre; Pallardy, Marc; Spindeldreher, Sebastian; Deisenhammer, Florian; Fogdell-Hahn, Anna; de Vries, Niek.
Afiliação
  • van der Weele L; Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam UMC228, Location AMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute (AIII), Amsterdam UMC, Lo
  • Pollastro S; Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam UMC228, Location AMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute (AIII), Amsterdam UMC, Lo
  • van Schaik BDC; Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Infection & Immunity Institute (AIII), Amsterdam Public Health Research Institute, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
  • van Kampen AHC; Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Infection & Immunity Institute (AIII), Amsterdam Public Health Research Institute, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Niewold ITG; Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam UMC228, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Kuijpers TW; Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Warnke C; Department of Neurology, Medical Faculty, University Hospital of Cologne, Germany.
  • Jensen PEH; Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Kramer D; Sanofi-Aventis Germany, Frankfurt Am Main, Germany.
  • Ryner M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Hermanrud C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Dönnes P; SciCross AB, Skövde, Sweden.
  • Pallardy M; Université Paris-Saclay, INSERM, Inflammation Microbiome Immunopathologie, Faculté Pharmacie, Châtenay-Malabry, France.
  • Spindeldreher S; Integrated Biologix GmbH, Basel, Switzerland.
  • Deisenhammer F; Innsbruck Medical University, Innsbruck, Austria.
  • Fogdell-Hahn A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • de Vries N; Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam UMC228, Location AMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute (AIII), Amsterdam UMC, Lo
J Neuroimmunol ; 370: 577932, 2022 09 15.
Article em En | MEDLINE | ID: mdl-35853357
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: J Neuroimmunol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: J Neuroimmunol Ano de publicação: 2022 Tipo de documento: Article